News & Updates

In women with nonspecific vaginitis, treatment with a medical device that uses vaginal ovules not only helps alleviate symptoms but also works to restore the normal pH and reduce signs of vaginal inflammation, as reported in a study.

Treatment with oral valacyclovir appears to reduce the rates of vertical transmission of cytomegalovirus (CMV) infection, with a low frequency of side effects, as shown in a study.

The use of levonorgestrel (LNG) plus piroxicam, as oral emergency contraception (EC) after unprotected sexual intercourse (UPSI), resulted in a significantly greater number of pregnancies prevented compared with LNG plus placebo, according to a study presented at RCOG 2023.

For outpatient cervical ripening and labour induction, low-dose vaginal misoprostol has the most favourable risk-benefit profile, reducing the interval to delivery, according to the results of a systematic review and network meta-analysis.

In the first years of use, conjugated estrogens/bazedoxifene (CE/BZA) appears to be associated with slightly higher rates of endometrial cancer and endometrial hyperplasia compared with estrogen/progestin (EP) combination hormone therapy, according to a study.

Survivors of complicated monochorionic diamniotic (MCDA) twin pregnancies (ie, complicated twins) have a higher rate of adverse neurodevelopmental outcomes compared with uncomplicated twins, suggests a study presented at RCOG 2023.

Children conceived via fresh intracytoplasmic sperm injection (ICSI) are at higher risk of major malformations compared with those conceived via fresh in vitro fertilization (IVF), according to a study.

During pregnancy, a higher serum uric acid (SUA) to creatinine (sCr) ratio appears to elevate the risk of pre-eclampsia (PE) and adverse pregnancy outcomes, suggests a recent study.

The use of prophylactic tranexamic acid (TXA) prior to elective Caesarean section (CS) led to significantly lower blood loss in women, particularly those at high risk for postpartum haemorrhage (PPH), according to a study presented at RCOG 2023.

Treatment with mirvetuximab soravtansine, an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα), led to significantly better survival outcomes in women with platinum-resistant ovarian cancer (PROC) compared with the investigator’s choice of chemotherapy, according to the MIRASOL trial presented at ASCO 2023.